AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “hold” rating reaffirmed by analysts at Benchmark in a research note issued to investors on Monday,Benzinga reports.
A number of other research firms have also recently issued reports on ABCL. Stifel Nicolaus cut their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. KeyCorp lowered their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.
View Our Latest Report on ABCL
AbCellera Biologics Stock Down 0.8 %
Institutional Investors Weigh In On AbCellera Biologics
A number of institutional investors and hedge funds have recently made changes to their positions in ABCL. Arcadia Investment Management Corp MI acquired a new stake in shares of AbCellera Biologics in the 3rd quarter worth about $26,000. DKM Wealth Management Inc. purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $29,000. State of New Jersey Common Pension Fund D purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $36,000. Balyasny Asset Management L.P. purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $40,000. Finally, Mariner LLC purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $42,000. Institutional investors and hedge funds own 61.42% of the company’s stock.
AbCellera Biologics Company Profile
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Further Reading
- Five stocks we like better than AbCellera Biologics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Compound Interest and Why It Matters When Investing
- Tesla Stock: Finding a Bottom May Take Time
- What Are Earnings Reports?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.